Amlodipine

Generic Name: Amlodipine

Brand Names: Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 88150-42-9

Unique Ingredient Identifier: 1J444QC288

Background: Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .

Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Indication: Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)

• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%

Associated Conditions: Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina

Associated Therapies: -

Clinical Trials

Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients

Not Applicable

Completed

Conditions: Female Infertility Associated With Anovulation

Interventions: Drug: Clomifene citrate ( clomid 50 mg )
Drug: Amlodipine

First Posted Date: 2015-09-09

Last Posted Date: 2016-03-25

Lead Sponsor: Ahmed Fathy Ali Mohamed Ghanem

Target Recruit Count: 60

Registration Number: NCT02544776

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

Not Applicable

Conditions: Beta-Thalassemia
Iron Overload

Interventions: Drug: Amlodipine
Drug: Deferasirox

First Posted Date: 2015-06-17

Last Posted Date: 2016-10-26

Lead Sponsor: Kevin H.M. Kuo, MD, MSc, FRCPC

Target Recruit Count: 60

Registration Number: NCT02474420

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

RAS Peptide Profiles in Patients With Arterial Hypertension

Completed

Conditions: Essential Hypertension

Interventions: Drug: Perindopril
Drug: Olmesartan
Drug: Hydrochlorothiazide
Drug: Amlodipine

First Posted Date: 2015-05-20

Last Posted Date: 2019-02-22

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 107

Registration Number: NCT02449811

Locations: 🇨🇭
University Hospital, Basel, Switzerland

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

Not Applicable

Completed

Conditions: Essential Hypertension

Interventions: Drug: Lisinopril
Drug: Amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2015-04-09

Last Posted Date: 2018-11-15

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 42

Registration Number: NCT02412761

Locations: 🇺🇸
University of Texas at Houston Medical School; Pediatric Nephrology and Hypertension Clinics, Houston, Texas, United States

Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome

Phase 2

Conditions: Sleep Apnea Syndrome
Hypertension

Interventions: Drug: Amlodipine
Drug: metoprolol

First Posted Date: 2015-04-03

Last Posted Date: 2017-02-15

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 20

Registration Number: NCT02408172

Locations: 🇨🇳
Portable polysomnography, Suzhou, Jiangsu, China
🇭🇺
Twenty-four-hour ambulatory BP monitoring, Budapest, Hungary

Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Fimasartan
Drug: Amlodipine
Drug: Rosuvastatin

First Posted Date: 2015-03-25

Last Posted Date: 2015-07-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 50

Registration Number: NCT02397538

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of, Korea, Republic of

INTERVENCION Trial

Phase 4

Conditions: Blood Pressure, High

Interventions: Drug: Hydrochlorothiazide
Drug: Amlodipine
Drug: Telmisartan

First Posted Date: 2015-02-26

Last Posted Date: 2015-10-21

Lead Sponsor: Prevencion

Target Recruit Count: 120

Registration Number: NCT02373163

Locations: 🇵🇪
Centro de Investigacion PREVENCION, Arequipa, AQP, Peru

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Amlodipine 5mg
Drug: Amlodipine 5mg, Candesartan cilexetil 16mg
Drug: Amlodipine 10mg, Candesartan cilexetil 16mg

First Posted Date: 2015-02-23

Last Posted Date: 2023-05-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 180

Registration Number: NCT02368665

Locations: 🇰🇷
Hallym University Sungsim Hospital, Anyang-si, Korea, Republic of
🇰🇷
Inje University Busan Baik Hospital, Busan, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of

and more 16 locations